Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy

10 Jun 2014

Abstract excerpt

The receptor tyrosine kinases (RTKs) are key drivers of cancer progression and targets for drug therapy. A major challenge in anti-RTK treatment is the dependence of drug effectiveness on co-expression of multiple RTKs which defines resistance to single drug therapy. Reprogramming of the RTK network leading to alteration in RTK co-expression in response to drug intervention is a dynamic mechanism of acquired...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24918976
DOI: 10.3390/cells3020563

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer TherapyPMID 24918976Read ↗

Anticancer Target Combinations: Network-Informed Signaling-Based Approach to DiscoverySemantic proximity Read ↗

Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistanceSemantic proximity Read ↗

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancerSemantic proximity Read ↗

Combined kinome inhibition states are predictive of cancer cell line sensitivity to kinase inhibitor combination therapiesSemantic proximity Read ↗

Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanismSemantic proximity Read ↗

Regulatory network and spatial modeling reveal cooperative mechanisms of resistance and immune escape in ER <sub>+</sub> breast cancerSemantic proximity Read ↗

Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to TrastuzumabSemantic proximity Read ↗

Strategies to overcome drug resistance of receptor tyrosine kinaseaddicted cancer cells.Semantic proximity Read ↗

JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2–Targeted TherapiesSemantic proximity Read ↗

Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalitiesSemantic proximity Read ↗

A Rational Drug Combination Design to Inhibit Epithelial-Mesenchymal Transition in a Three-Dimensional MicroenvironmentSemantic proximity Read ↗

Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.